PharmaCyte Biotech, Inc.PMCB
Price (close)
$0.46
Market cap
$4.9M
P/E
—
Revenue (TTM)
$0
Net income
-$16.1M
Dividend yield
—
1-year total return
-53.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What PharmaCyte Biotech, Inc. does.
cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.”
The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC,
Scientific Committee (the “Scientific Committee”), chaired by Dr. Michael Abecassis. The Scientific Committee and our independent
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.6M | -$4.2M | -$4.3M | $333,763 | $30.7M | -$19.4M |
More on PMCB.
- PharmaCyte Biotech, Inc. summary
- PharmaCyte Biotech, Inc. financial statements
- PharmaCyte Biotech, Inc. key metrics
- PharmaCyte Biotech, Inc. health scores and style box
- PharmaCyte Biotech, Inc. earnings
- PharmaCyte Biotech, Inc. dividends
- PharmaCyte Biotech, Inc. valuation
- PharmaCyte Biotech, Inc. ownership and insiders
- PharmaCyte Biotech, Inc. peers
Figures from PharmaCyte Biotech, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.